KIR2DL2 靶点蛋白|抗体药物|临床药物信息

KIR2DL2信息

英文名称：Killer cell immunoglobulin-like receptor 2DL2
中文名称：杀伤细胞免疫球蛋白样受体2DL2
靶点别称：CD158b1 Antigen，CD158b，P58.2，Receptors， KIR2DL2，CD158k，Cl-43，p58 NK receptor CL-43，CD158B1，Natural killer-associated transcript 6，NKAT6，Killer cell immunoglobulin-like receptor 2DL2，KIR2DL2，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 2，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 2，P58 Natural Killer Cell Receptor Clone CL-43，CD158 Antigen-Like Family Member B1，MHC Class I NK Cell Receptor，NKAT-6

上市药物数量：0
临床药物数量：1
最高研发阶段：临床二期

KIR2DL2产品列表

筛选结果

产品库

在线 (1)

物种

Human (1)

标签

Fc Tag (1)

属性

Protein (1)

标记

Unconjugated (1)

货号	物种	产品描述	蛋白结构	纯度	活性
KI2-H5255	Human	Human KIR2DL2 / CD158b1 / NKAT-6 Protein, Fc Tag

KIR2DL2 分子别名

CD158b1

KIR2DL2 分子背景

Killer cell immunoglobulin-like receptor 2DL2(KIR2DL2), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. KIR2DL2 and KIR2DL3, regulate the activation of natural killer cells (NK) by interacting with the human leukocyte antigen-C1 (HLA-C1) group of molecules. KIR2DL2, KIR2DL3 and HLA-C1 are highly polymorphic, with this variation being associated with differences in the onset and progression of some human diseases.

KIR2DL2 前沿进展

KIR2DL2临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
Lirilumab	IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015	临床二期	诺和诺德制药	骨髓瘤, 头颈部鳞状细胞癌, 阴燃多发性骨髓瘤, 肿瘤, 多发性骨髓瘤, 膀胱癌, 急性髓细胞样白血病, 双表型急性白血病	详情

会议日历

会议一览

KIR2DL2